IP Library Patent Application 13594941
Patent Application
App. No. 13/594,941

METHOD FOR TREATING BRAIN CANCER

Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US None
App. No.
13/594,941
Abstract

Methods and compositions for treating brain cancer are disclose including refractory brain cancer.

Claims (22)

1 . A method of treating brain cancer comprising administering to a patient in need of treatment a therapeutically effective amount of a compound of Formula (I) or a pharmaceutically acceptable salt thereof

wherein R 1 represents hydrogen, a halogen or a sulfono group SO 3 M, in which M is a metal ion, and R 2 represents hydrogen, or R 1 is Cl and R 2 is I.

2 . The method of claim 1 , said compound is tris(8-quinolinolato)gallium(III).

3 . The method of claim 2 , wherein said brain cancer is not glioblastoma.

4 . The method of claim 2 , wherein said brain cancer is astrocytoma.

5 . The method of claim 2 , wherein said brain cancer is glioblastoma.

6 . The method of claim 2 , wherein said brain cancer is a refractory brain cancer.

7 . The method of claim 2 , wherein said brain cancer was previously treated with BCNU.

8 . The method of claim 7 , further comprising administering to said patient a therapeutically effective amount of temozolomide.

9 . The method of claim 2 , wherein said brain cancer was previously treated with temozolomide.

10 . The method of claim 9 , further comprising administering to said patient a therapeutically effective amount of temozolomide.

11 . The method according to claims 2 , further comprising administering to said patient a therapeutically effective amount of temozolomide.

12 . A kit comprising:

an effective amount of a compound of Formula (I)

wherein R 1 represents hydrogen, a halogen or a sulfono group SO 3 M, in which M is a metal ion, and R 2 represents hydrogen, or R 1 is Cl and R 2 is I, or a pharmaceutically acceptable salt thereof; and

an effective amount of temozolomide.

13 . The kit of claim 12 , wherein said compound is tris(8-quinolinolato)gallium(III).

14 . A pharmaceutical composition comprising:

an effective amount of a compound of Formula (I)

wherein R 1 represents hydrogen, a halogen or a sulfono group SO 3 M, in which M is a metal ion, and R 2 represents hydrogen, or R 1 is Cl and R 2 is I, or a pharmaceutically acceptable salt thereof; and

an effective amount of temozolomide.

15 . The pharmaceutical composition of claim 14 , wherein said compound is tris(8-quinolinolato)gallium(III).

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 3, 2013
From: NIIKI PHARMA INC.
To: NIIKI PHARMA AQUISITION CORP. 2
Reel/Frame 030740/0100 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 19, 2012
From: SHESHBARADARAN, HOOSHMAND; BAERGA, REBECCA; COBB, JENEL; VALIAHDI, SEIED MOJTABA; KEPPLER, BERNHARD
To: NIIKI PHARMA INC.
Reel/Frame 029155/0452 →